Your search for tofacitinib returned 3 results

Results of the ORAL Surveillance study showed a higher risk for major adverse CV events and venous thromboembolism with tofacitinib vs TNFis.

Researchers analyzed baseline and week 12 predictors of early response to mirikizumab to determine clinical outcomes by week 52.

The data were compared with the 2018 ACG and 2020 AGA guidelines for UC and the 2019 ACG and 2021 AGA guidelines for CD.